R Squared’s Monte Rosa Therapeutics GLUE Stock Holding History

R Squared’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300	Closed	-$2.08K	–	765
2024 Q4	$2.08K	Buy	+300	New	+$2.25K	﹤0.01%	1462

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

R Squared's GLUE Position: Q1 2025 in Review

R Squared sold out of Monte Rosa Therapeutics (GLUE) in Q1 2025, closing a stake of 300 shares — an estimated $2.08K sold.

R Squared first reported a position in GLUE in Q4 2024 and held it in 1 quarter. The position peaked at $2.08K in Q4 2024. 105 funds tracked by Wall St. Rank hold GLUE as of Q1 2025.

R Squared reported no remaining Monte Rosa Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 300 Monte Rosa Therapeutics shares in Q1 2025, an estimated $2.08K.
R Squared first reported a position in Monte Rosa Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Monte Rosa Therapeutics position peaked at $2.08K in Q4 2024.
105 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.